Literature DB >> 9240353

Stabilized analogs of thymopentin. 1. 4,5-Ketomethylene pseudopeptides.

J I DeGraw1, R G Almquist, C K Hiebert, W T Colwell, J Crase, T Hayano, A K Judd, L Dousman, R L Smith, W R Waud, I Uchida.   

Abstract

The pentapeptide, thymopentin (Arg1-Lys2-Asp3-Val4-Tyr5) is known for its activity as an immunomodulating drug, but with limited half-life in plasma. In this first paper of a series of three studies, the synthesis of analogs stabilized at the peptide bond between the C-terminal amino acids via insertion of a ketomethylene moiety is described. N-Blocked pseudopeptides containing Val(k)Phe, Ala(k)Phe, and Val(k)Val units were prepared and attached to chloromethyl Merrifield resin via the carboxy terminal. Removal of the N-BOC group by trifluoroacetic acid was followed by sequential coupling with N-BOC dipeptides of aspartic acid to yield resin-bound N-BOC pseudotetrapeptides. Removal of N-BOC and coupling with N-BOC-r-N-tosylarginine followed by total cleavage of blocking groups and resin by HF afforded the target pseudopentapeptides. The analogs were found to compete favorably with thymopentin for binding to CEM cells, but binding was reduced by about 20-30% on average. All analogs showed significant enhancement of half-life versus thymopentin in mouse serum, but most showed only modest improvement in human serum. Insertion of proline or norleucine at position 2 in the chain caused a substantial increase in half-life (3-4-fold), while N-methylnorleucine conferred complete stability in the analogs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9240353     DOI: 10.1021/jm950803a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  A practical, two-step synthesis of 2-substituted 1,3-butadienes.

Authors:  Sushmita Sen; Swapnil Singh; Scott McN Sieburth
Journal:  J Org Chem       Date:  2009-04-03       Impact factor: 4.354

2.  Design and Development of a Novel Peptide for Treating Intestinal Inflammation.

Authors:  Lulu Zhang; Xubiao Wei; Rijun Zhang; Jim N Petitte; Dayong Si; Zhongxuan Li; Junhao Cheng; Mengsi Du
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

3.  A Novel Peptide Ameliorates LPS-Induced Intestinal Inflammation and Mucosal Barrier Damage via Its Antioxidant and Antiendotoxin Effects.

Authors:  Lulu Zhang; Xubiao Wei; Rijun Zhang; Dayong Si; James N Petitte; Baseer Ahmad; Manyi Zhang
Journal:  Int J Mol Sci       Date:  2019-08-15       Impact factor: 5.923

4.  C-Terminal Amination of a Cationic Anti-Inflammatory Peptide Improves Bioavailability and Inhibitory Activity Against LPS-Induced Inflammation.

Authors:  Lulu Zhang; Xubiao Wei; Rijun Zhang; Matthew Koci; Dayong Si; Baseer Ahmad; Henan Guo; Yanfei Hou
Journal:  Front Immunol       Date:  2021-02-05       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.